The FDA approved AstraZeneca's drug Tagrisso as a first-line treatment for patients with metastatic non-small cell lung cancer with a specific genetic mutation, the company announced April 18.
The agency previously approved Tagrisso to treat patients whose lung cancer worsened after treatment with a different drug or those who developed a secondary genetic mutation, according to Reuters.
Under the new approval, patients whose tumors have an epidermal growth factor receptor mutation may take Tagrisso as an initial treatment. Clinicians identify the mutation via an FDA-approved detection test.